Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Off-the-Shelf Chimeric Antigen Receptor T Cells: How Do We Get There?

Literature DB >> 33750078

Off-the-Shelf Chimeric Antigen Receptor T Cells: How Do We Get There?

Abstract

ABSTRACT: Banked chimeric antigen receptor (CAR) T cells immediately available for off-the-shelf (OTS) application can solve key limitations of patient-specific CAR T-cell products while retaining their potency. The allogeneic nature of OTS cell therapies requires additional measures to minimize graft-versus-host disease and host-versus-graft immune rejection in immunocompetent recipients. In this review, we discuss engineering and manufacturing strategies aimed at minimizing unwanted interactions between allogeneic CAR T cells and the host. Overcoming these limitations will improve safety and antitumor potency of OTS CAR T cells and facilitate their wider use in cancer therapy.

Entities: Chemical

Mesh：

Substances：

Year: 2021 PMID： 33750078 PMCID： PMC8118392 DOI： 10.1097/PPO.0000000000000511

Source DB: PubMed Journal: Cancer J ISSN： 1528-9117 Impact factor: 3.360

73 in total

1. MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function.

Authors: H Das; V Groh; C Kuijl; M Sugita; C T Morita; T Spies; J F Bukowski
Journal: Immunity Date: 2001-07 Impact factor: 31.745

2. CD1c as a target recognition structure for human T lymphocytes: analysis with peripheral blood gamma/delta cells.

Authors: F Faure; S Jitsukawa; C Miossec; T Hercend
Journal: Eur J Immunol Date: 1990-03 Impact factor: 5.532

3. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.

Authors: Reuben Benjamin; Charlotte Graham; Deborah Yallop; Agnieszka Jozwik; Oana C Mirci-Danicar; Giovanna Lucchini; Danielle Pinner; Nitin Jain; Hagop Kantarjian; Nicolas Boissel; Marcela V Maus; Matthew J Frigault; André Baruchel; Mohamad Mohty; Athos Gianella-Borradori; Florence Binlich; Svetlana Balandraud; Fabien Vitry; Elisabeth Thomas; Anne Philippe; Sylvain Fouliard; Sandra Dupouy; Ibtissam Marchiq; Maria Almena-Carrasco; Nicolas Ferry; Sylvain Arnould; Cyril Konto; Paul Veys; Waseem Qasim
Journal: Lancet Date: 2020-12-12 Impact factor: 79.321

4. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.

Authors: Cesar Sommer; Bijan Boldajipour; Tracy C Kuo; Trevor Bentley; Janette Sutton; Amy Chen; Tao Geng; Holly Dong; Roman Galetto; Julien Valton; Thomas Pertel; Alexandre Juillerat; Annabelle Gariboldi; Edward Pascua; Colleen Brown; Sherman M Chin; Tao Sai; Yajin Ni; Philippe Duchateau; Julianne Smith; Arvind Rajpal; Thomas Van Blarcom; Javier Chaparro-Riggers; Barbra J Sasu
Journal: Mol Ther Date: 2019-04-08 Impact factor: 11.454

5. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors: Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal: N Engl J Med Date: 2018-02-01 Impact factor: 91.245

6. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1.

Authors: Emmanuel Treiner; Livine Duban; Seiamak Bahram; Mirjana Radosavljevic; Valerie Wanner; Florence Tilloy; Pierre Affaticati; Susan Gilfillan; Olivier Lantz
Journal: Nature Date: 2003-03-13 Impact factor: 49.962

7. Differentiation of human peripheral blood Vδ1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells.

Authors: Daniel V Correia; Manuela Fogli; Kelly Hudspeth; Maria Gomes da Silva; Domenico Mavilio; Bruno Silva-Santos
Journal: Blood Date: 2011-06-01 Impact factor: 22.113

8. An invariant T cell receptor alpha chain defines a novel TAP-independent major histocompatibility complex class Ib-restricted alpha/beta T cell subpopulation in mammals.

Authors: F Tilloy; E Treiner; S H Park; C Garcia; F Lemonnier; H de la Salle; A Bendelac; M Bonneville; O Lantz
Journal: J Exp Med Date: 1999-06-21 Impact factor: 14.307

9. Tumor-infiltrating mucosal-associated invariant T (MAIT) cells retain expression of cytotoxic effector molecules.

Authors: Patrik Sundström; Louis Szeponik; Filip Ahlmanner; Malin Sundquist; Justin S B Wong; Elinor Bexe Lindskog; Bengt Gustafsson; Marianne Quiding-Järbrink
Journal: Oncotarget Date: 2019-04-19

10. Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer.

Authors: Yan Xu; Zheng Xiang; Mohammed Alnaggar; Léonce Kouakanou; Jiawei Li; Junyi He; Jiashuang Yang; Yi Hu; Yan Chen; Li Lin; Jianlei Hao; Jingxia Li; Jibing Chen; Man Li; Qingling Wu; Christian Peters; Qinghua Zhou; Jianshuang Li; Yingqing Liang; Xiaohua Wang; Baohui Han; Meili Ma; Dieter Kabelitz; Kecheng Xu; Wenwei Tu; Yangzhe Wu; Zhinan Yin
Journal: Cell Mol Immunol Date: 2020-09-16 Impact factor: 22.096

1 in total

Review 1. Advances in Universal CAR-T Cell Therapy.

Authors: Haolong Lin; Jiali Cheng; Wei Mu; Jianfeng Zhou; Li Zhu
Journal: Front Immunol Date: 2021-10-06 Impact factor: 7.561

1 in total